Citius Pharmaceuticals Inc.

2.12-0.0100-0.47%Vol 1.11M1Y Perf 105.83%
Sep 23rd, 2021 12:46 DELAYED
BID2.12 ASK2.13
Open2.16 Previous Close2.13
Pre-Market- After-Market-
 - -%  - -
Target Price
6.00 
Analyst Rating
Strong Buy 1.00
Potential %
183.02 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
33.88 
Earnings Rating
Strong Sell
Market Cap309.48M 
Earnings Date
13th Aug 2021
Alpha-0.01 Standard Deviation0.29
Beta1.53 

Today's Price Range

2.112.17

52W Range

0.87004.56

5 Year PE Ratio Range

-5.80-2.10

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
2.40%
1 Month
11.52%
3 Months
-46.48%
6 Months
7.04%
1 Year
105.83%
3 Years
20.34%
5 Years
-77.46%
10 Years
-

TickerPriceChg.Chg.%
CTXR2.12-0.0100-0.47
AAPL146.740.89000.61
GOOG2 841.0122.24000.79
MSFT299.891.31000.44
XOM57.081.87003.39
WFC48.000.92001.95
JNJ165.651.72001.05
FB346.583.37000.98
GE103.514.97005.04
JPM161.245.33003.42
Earnings HistoryEstimateReportedSurprise %
Q03 2021-0.05-0.050.00
Q02 2021-0.08-0.0450.00
Q01 2021--0.15-
Q03 2019-0.06-0.20-233.33
Q02 2019-0.20-0.200.00
----
----
----
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.06-20.00Negative
9/2021 FY-0.28-12.00Negative
12/2021 QR0.070.00-
9/2022 FY0.370.00-
Next Report Date-
Estimated EPS Next Report-0.05
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.11M
Shares Outstanding145.98M
Shares Float133.67M
Trades Count2.67K
Dollar Volume36.96M
Avg. Volume9.28M
Avg. Weekly Volume2.36M
Avg. Monthly Volume3.27M
Avg. Quarterly Volume5.66M

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) stock closed at 2.13 per share at the end of the most recent trading day (a 5.97% change compared to the prior day closing price) with a volume of 3.02M shares and market capitalization of 309.48M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Citius Pharmaceuticals Inc. CEO is Myron Z. Holubiak.

The one-year performance of Citius Pharmaceuticals Inc. stock is 105.83%, while year-to-date (YTD) performance is 108.82%. CTXR stock has a five-year performance of -77.46%. Its 52-week range is between 0.87 and 4.56, which gives CTXR stock a 52-week price range ratio of 33.88%

Citius Pharmaceuticals Inc. currently has a PE ratio of -6.70, a price-to-book (PB) ratio of 2.22, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.29%, a ROC of -28.43% and a ROE of -28.34%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Citius Pharmaceuticals Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Citius Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Citius Pharmaceuticals Inc. is Strong Buy (1), with a target price of $6, which is +183.02% compared to the current price. The earnings rating for Citius Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Citius Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Citius Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 29.24, ATR14 : 0.13, CCI20 : 11.44, Chaikin Money Flow : 0.00, MACD : 0.01, Money Flow Index : 46.52, ROC : 1.43, RSI : 55.42, STOCH (14,3) : 55.88, STOCH RSI : 1.00, UO : 49.34, Williams %R : -44.12), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Citius Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. It is primarily operating within the critical care and cancer care market segments.

CEO: Myron Z. Holubiak

Telephone: +1 908 967-6677

Address: 11 Commerce Drive, Cranford 07016, NJ, US

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

48%52%

Bearish Bullish

66%34%

News

Stocktwits